Mira Pharmaceuticals (MIRA) Non-cash Items (2024 - 2025)
Mira Pharmaceuticals' (MIRA) quarterly Non-cash Items came in at $6.0 million in Q4 2025, up 4351.24% year-on-year from $135200.0 in Q4 2024, and up 76.92% quarter-over-quarter from $3.4 million in Q3 2025.
Mira Pharmaceuticals (MIRA) Non-cash Items (2024 - 2025) Analysis & Trends
Mira Pharmaceuticals has disclosed Non-cash Items across 2 years of filings, most recently posting $6.0 million for Q4 2025.
- Non-cash Items for Q4 2025 came in at $6.0 million, up 4351.24% year-over-year; the trailing twelve-month figure through Dec 2025 was $6.0 million (up 4351.24% YoY), and the FY2025 annual result was $6.0 million, up 4351.24% from the prior year.
- Non-cash Items came in at $6.0 million for Q4 2025 at Mira Pharmaceuticals, up from $3.4 million in the prior quarter.
- In the past five years, Non-cash Items ranged from a high of $6.0 million in Q4 2025 to a low of $135200.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn |
| 10 | Mira Pharmaceuticals | 22.73 Mn | 11.70 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.02 Mn |
| Dec 31, 2025 | 6.02 Mn |
| Sep 30, 2025 | 3.40 Mn |
| Sep 30, 2025 | 3.40 Mn |
| Jun 30, 2025 | 3.99 Mn |
| Jun 30, 2025 | 3.99 Mn |
| Mar 31, 2025 | 2.70 Mn |
| Mar 31, 2025 | 2.70 Mn |
| Dec 31, 2024 | 135,200.00 |
| Dec 31, 2024 | 135,200.00 |